Marimed (MRMD) Asset Writedowns and Impairment (2020 - 2026)

Marimed (MRMD) has reported Asset Writedowns and Impairment for 7 consecutive years, with $505000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 97.27% year-over-year to $505000.0 in Q2 2026; TTM through Jun 2026 was $519000.0, a 61.12% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, up 570.83% from the prior year.
• Asset Writedowns and Impairment was $505000.0 for Q2 2026 at Marimed, up from $76000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $3.7 million in Q4 2022 and troughed at -$205000.0 in Q4 2024.
• A 5-year average of $416187.5 and a median of $50000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment surged 52728.57% in 2022 and slumped 405.0% in 2023, its largest moves.
• Over 5 years, Asset Writedowns and Impairment stood at $3.7 million in 2022, then sank by 93.37% to $245000.0 in 2023, then plunged by 183.67% to -$205000.0 in 2024, then jumped by 129.27% to $60000.0 in 2025, then surged by 741.67% to $505000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $505000.0 (Q2 2026), $76000.0 (Q1 2026), and $60000.0 (Q4 2025), per Business Quant data.